Cellectis is a clinical-stage biopharmaceutical company developing the Next-Generation CAR T-Cells to Cure Cancer.
The development of next-generation allogeneic CAR T cells to address these issues is an active area of research. In this Review, we analyse the different sources of T cells for optimal allogeneic CAR-T cell therapy and describe the different technological approaches, mainly based on gene editing...
Allogeneic BMTCAR T-cell therapyDiffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma in adults. Although curable in the majority of cases, a substantial portion of patients will experience disease relapse and will die from their lymphoma. This review is aimed at ...
Here we present a universal CAR T cell approach using T cells from healthy donors. Key features of UCART123 include the TCRαβ knock out using TALEN® gene-editing technology to minimize the risk of GvHD; and, as safety feature, includes expression of the “safety switch” RQR8, allowing...
Martino M, Alati C, Canale FA, Musuraca G, Martinelli G, Cerchione C. A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia.Int J Mol Sci. 2021;22(4):2150. Published 2021 Feb 21.A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute ...
Although chimeric antigen receptor T (CAR-T) cells have been proven to be an effective way of treating B cell malignancies, a lot of patients could not ben
Encyclopedia Wikipedia Related to allogeneic:zooplastic Graphic Thesaurus🔍 DisplayON AnimationON Legend Synonym Antonym Related </>embed</> xenogeneic allogeneic Antonyms for allogeneic adjdenoting or relating to cells or tissues from individuals belonging to the same species but genetically dissimilar (...
Then, we review the occurrence of toxicities and GVHD after allo-HSCT in relapsed patients who were treated with CAR-T cells. Finally, we review the clinical trial registrations and therapeutic time window for the infusion of CAR-T cells after allo- HSCT. Allogeneic CAR-T cells for relapsed...
(r/r MM) in the CaMMouflage Phase 1 trial. CB-011 is an allogeneic anti-BCMA CAR-T cell therapy engineered using Cas12a chRDNA technology. CB-011 is the first allogeneic CAR-T cell therapy in the clinic, to Caribou’s knowledge, that is...
et al. Dose fractionation of CAR-T cells. A systematic review of clinical outcomes. J. Exp. Clin. Cancer Res. 42, 11 (2023). Article PubMed PubMed Central Google Scholar Gauthier, J. et al. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for ...